A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CART-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

被引：25
|
作者：
Shah, Nirav N. [1 ]
Zhu, Fenlu [2 ]
Taylor, Carolyn [2 ]
Schneider, Dina [3 ]
Krueger, Winfried [3 ]
Worden, Andrew [3 ]
Yim, Sharon [2 ]
Fenske, Timothy S. [1 ]
Hamadani, Mehdi [1 ]
Johnson, Bryon [4 ]
Dropulic, Boro [5 ]
Orentas, Rimas [3 ]
Hari, Parameswaran [6 ]
机构：
[1] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Lentigen Technol Inc, Gaithersburg, MD USA
[4] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[5] Lentigen, Gaithersburg, MD USA
[6] Med Coll Wisconsin, Dept Med, Menomonee Falls, WI USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110194
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4193
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
    Cooper, Brenda W.
    Gallogly, Molly Megan
    Metheny, Leland
    Klisovic, Rebecca B.
    Boughan, Kirsten Marie
    Koc, Jane Reese
    Wu, Darong
    Deng, Changchun
    Van Besien, Koen
    Tupta, Rose
    Schneider, Dina
    Ciarrone, Lisa
    de Lima, Marcos
    Caimi, Paolo F.
    Tomlinson, Benjamin K.
    BLOOD, 2023, 142
  • [22] Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
    Chong, Elise A.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Winchell, Nicole
    Napier, Ellen
    Mato, Anthony R.
    Melenhorst, J. Joseph
    Ruella, Marco
    Lacey, Simon F.
    June, Carl H.
    Schuster, Stephen J.
    BLOOD, 2018, 132
  • [23] Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Heng, Gang
    Jia, Jiankun
    Li, Shiqi
    Fu, Gang
    Wang, Meiling
    Qin, Dabing
    Li, Yunyan
    Pei, Li
    Tian, Xiaobo
    Zhang, Jiasi
    Wu, Yi
    Xiang, Shali
    Wan, Jia
    Zhu, Wei
    Zhang, Pei
    Zhang, Qianzhen
    Peng, Xi
    Wang, Linling
    Wang, Ping
    Wei, Zhihao
    Zhang, Yingzi
    Wang, Guiqin
    Chen, Xue
    Zhang, Chengcheng
    Sun, Yanni
    Zhao, Wenxu
    Fan, Yahan
    Yang, Zhi
    Chen, Jieping
    Qian, Cheng
    CLINICAL CANCER RESEARCH, 2020, 26 (07) : 1606 - 1615
  • [24] Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial
    Ying, Zhitao
    Xie, Yan
    Zheng, Wen
    Liu, Weiping
    Lin, Ningjing
    Tu, Meifeng
    Wang, Xiaopei
    Ping, Lingyan
    Deng, Lijuan
    Zhang, Chen
    Wu, Meng
    Feng, Feier
    Du, Tingting
    Tang, Yongjing
    Su, Fang
    Guo, Ziyu
    Li, James
    Song, Yuqin
    Zhu, Jun
    BONE MARROW TRANSPLANTATION, 2023, 58 (03) : 288 - 294
  • [25] Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial
    Zhitao Ying
    Yan Xie
    Wen Zheng
    Weiping Liu
    Ningjing Lin
    Meifeng Tu
    Xiaopei Wang
    Lingyan Ping
    Lijuan Deng
    Chen Zhang
    Meng Wu
    Feier Feng
    Tingting Du
    Yongjing Tang
    Fang Su
    Ziyu Guo
    James Li
    Yuqin Song
    Jun Zhu
    Bone Marrow Transplantation, 2023, 58 : 288 - 294
  • [26] Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
    Yan, Zi-Xun
    Li, Li
    Wang, Wen
    OuYang, Bin-Shen
    Cheng, Shu
    Wang, Li
    Wu, Wen
    Xu, Peng-Peng
    Muftuoglu, Muharrem
    Hao, Ming
    Yang, Su
    Zhang, Mu-Chen
    Zheng, Zhong
    Li, James
    Zhao, Wei-Li
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 6995 - 7003
  • [27] Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
    Li, Sujun
    Xue, Lei
    Wang, Min
    Qiang, Ping
    Xu, Hui
    Zhang, Xuhan
    Kang, Wenyao
    You, Fengtao
    Xu, Hanying
    Wang, Yu
    Liu, Xin
    Yang, Lin
    Wang, Xingbing
    ONCOTARGETS AND THERAPY, 2019, 12 : 5627 - 5638
  • [28] Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
    Shah, Nirav N.
    Johnson, Bryon D.
    Schneider, Dina
    Zhu, Fenlu
    Szabo, Aniko
    Keever-Taylor, Carolyn A.
    Krueger, Winfried
    Worden, Andrew A.
    Kadan, Michael J.
    Yim, Sharon
    Cunningham, Ashley
    Hamadani, Mehdi
    Fenske, Timothy S.
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    NATURE MEDICINE, 2020, 26 (10) : 1569 - +
  • [29] Salvage Radiotherapy for Relapsed/Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor T-Cell (CART) Therapy
    Wright, C. M.
    Yegya-Raman, N.
    Baron, J.
    Lee, D. Y.
    Chong, E. A.
    LaRiviere, M. J.
    Maity, A.
    Plastaras, J. P.
    Paydar, I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S132 - S133
  • [30] DEVELOPING IN-HOUSE, POINT-OF-CARE MANUFACTURED ANTI-CD19 CHIMAERIC ANTIGEN RECEPTOR (CAR)-T CELLS
    Chan, Nelson Chun Ngai
    Loaiza, Sandra
    Uddin, Shab
    Aina, Edward
    Cook, Lucy
    Palanicawandar, Renuka
    Bara, Anna
    Olavarria, Eduardo
    Apperley, Jane
    Karadimitris, Anastasios
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 209 - 210
12345